Preview

Osteoporosis and Bone Diseases

Advanced search

High-doses of cholecalciferol for vitamin D deficiency treatment: results of an open-label, multicenter, comparative, randomized trial

https://doi.org/10.14341/osteo12697

Abstract

Background: Vitamin D deficiency have serious medical, social and economic consequences for human health and require timely diagnosis and adequate correction.

Aim: Evaluation of the efficacy and safety of therapy with Fortedetrim soft capsules (MEDANA PHARMA AO, Poland) using saturating and maintenance doses compared to therapy with Vigantol®, an oily solution for oral administration (Merck KGaA, Germany) in patients with vitamin D deficiency.

Materials and methods: The study included 150 patients with vitamin D deficiency (less than 20 ng/ml) aged 18 to 75 years, who were randomized into 3 groups in a 1:1:1 ratio (50 people each). Fortedetrim capsules were used in two groups during the first four weeks 50,000 IU once a week (5 capsules 10,000 IU each) and 56,000 IU — 8,000 IU daily (2 capsules 4000 IU), and Vigantol® was used in the comparison group 1000 IU daily (2 drops). Over the next 12 weeks, patients received supportive therapy — in the first group, Fortedetrim 10,000 IU was used once a week, in the second — Fortedetrim 2,000 IU daily (14,000 IU per week); the comparison group continued to take Vigantol® 1000 IU daily.

Results: As a result of evaluating the data on the results of stages I and II of the clinical study Fortedetrim in comparison with Vigantol®, the hypothesis was proved that the high-dose drug Fortedetrim (capsules of 2000, 4000 and 10000 IU) is superior to the drug Vigantol® (drops, 1000 IU daily). Nevertheless, it should be noted that long-term intake of colecalciferol at a dose of 1000 IU daily by 20 weeks allowed 36% of participants to reach a level of 30 ng/ml, but this is significantly less than in groups using high-dose drugs. There were no differences in the number of adverse events during the study, their degree and the relationship with drug intake between the treatment and comparison groups.

Conclusion: The use of the drug Fortedetrim in saturating doses is effective and safe for the treatment of adult patients with vitamin D deficiency. However, an individual approach to its replenishment is required (taking into account compliance, the degree of obesity, impaired absorption of calcium and vitamin D), since not all patients in the applied saturation regimes, the target values of vitamin D in the blood were reached. 

About the Authors

Liudmila Y. Rozhinskaya
The National Medical Research Center for Endocrinology
MD, PhD, Professor


Ekaterina A. Pigarova
The National Medical Research Center for Endocrinology
MD, PhD


Anastasia A. Bagretsova
Northern Medical Clinical Center named after N.А. Semashko
MD


Andrey F. Verbovoy
«Diabetes Center» LLC
MD, PhD, professor


Natalia G. Kondratyeva
«Aurora» LLC
MD


Olga A. Vasilevskaya
LLC «The Medical diagnostic center»
MD


Vasily B. Vasilyuk
LLC «Research Center Eco-safety»
MD, PhD, professor


Maria V. Manko
CJSC «Heirs»
MD


Victor B. Shunkov
Private educational institution «Clinical hospital» Russian Railways-Medicine «of St. Petersburg»
MD, PhD


Tatiana A. Grebennikova
The National Medical Research Center for Endocrinology
MD, PhD


References

1. Holick MF. Vitamin D Deficiency. N. Engl. J. Med. 2007;357(3):266-281. doi: https://doi.org/10.1056/NEJMra070553.

2. Scragg R, Waayer D, Stewart AW, et al. The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. The Journal of Steroid Biochemistry and Molecular Biology. 2016;164:318-325. doi: https://doi.org/10.1016/j.jsbmb.2015.09.010.

3. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. Available from: https://www.ncbi.nlm.nih.gov/books/NBK56070/ doi: https://doi.org/10.17226/13050

4. Pigarova E.A., Rozhinskaya L.Y., Belaya J.E., Dzeranova LK, Karonova TL, Ilyin AV, Melnichenko GA, Dedov II. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.). doi: https://doi.org/10.14341/probl201662460-84

5. Cranney A, Horsley T, O’Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. 2007. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK74011/

6. Scragg R, Waayer D, Stewart AW, et al. The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. The Journal of Steroid Biochemistry and Molecular Biology. 2016;164:318-325. doi: https://doi.org/10.1016/j.jsbmb.2015.09.010.

7. Scragg R, Khaw K-T, Toop L, et al. Monthly HighDose Vitamin D Supplementation and Cancer Risk. JAMA Oncology. 2018;4(11):e182178. doi: https://doi.org/10.1001/jamaoncol.2018.2178.

8. Soe HHK, Abas ABL, Than NN, et al. Vitamin D supplementation for sickle cell disease. Cochrane Database Syst Rev. 2017. doi: https://doi.org/10.1002/14651858.CD010858.pub2.

9. Schleck M-L, Souberbielle J-C, Jandrain B, et al. A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency. Nutrients. 2015;7(7):5413-5422. doi: https://doi.org/10.3390/nu7075227.

10. Ilahi M, Armas LAG, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. The American Journal of Clinical Nutrition. 2008;87(3):688-691. doi: https://doi.org/10.1093/ajcn/87.3.688.

11. Dudenkov DV, Yawn BP, Oberhelman SS, et al. Changing Incidence of Serum 25-Hydroxyvitamin D Values Above 50 ng/mL: A 10-Year Population-Based Study. Mayo Clin. Proc. 2015;90(5):577-586. doi: https://doi.org/10.1016/j.mayocp.2015.02.012.

12. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern. Med. Rev. 2008;13(1):6-20.

13. Quack Lötscher KC, l’Allemand D, Bischoff-Ferrari HA, Burckhardt P. Vitamin-D deficiency: Evidence, safety, and recommendations for the Swiss population. Bern, Switzerland: Federal Office of Public Health, 2012

14. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocr. Metab. 2011;96(7):1911-1930. doi: https://doi.org/10.1210/jc.2011-0385.

15. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. The American Journal of Clinical Nutrition. 2008;87(4):1080S-1086S. doi: https://doi.org/10.1093/ajcn/87.4.1080S.

16. Petrushkina AA, Pigarova EA, Rozhinskaya LY. The prevalence of vitamin D deficiency in Russian Federation. Osteoporosis and Bone Diseases. 2019;21(3):15-20. (In Russ.) doi: https://doi.org/10.14341/osteo10038

17. Pigarova E.A. Summary of clinical guidelines of the Russian association of endocrinologists vitamin D deficiency in adults: diagnosis, treatment and prevention. Osteoporosis and Bone Diseases. 2015;18(2):29-32. (In Russ.) doi: https://doi.org/10.14341/osteo2015229-32

18. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture Prevention With Vitamin D Supplementation. JAMA. 2005;293(18):2257. doi: https://doi.org/10.1001/jama.293.18.2257.

19. Gagnon C, Lu ZX, Magliano DJ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care. 2011;34(5):1133-1138. doi: https://doi.org/10.2337/dc10-2167.

20. Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis. Maturitas. 2010;65(3):225-236. doi: https://doi.org/10.1016/j.maturitas.2009.12.013.

21. Drechsler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur. Heart J. 2010;31(18):2253-2261. doi: https://doi.org/10.1093/eurheartj/ehq246.

22. Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM. 2007;100(4):185-192. doi: https://doi.org/10.1093/qjmed/hcm005.

23. Schnatz PF, Jiang X, Vila-Wright S, et al. Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women’s Health Initiative calcium/ vitamin D randomized trial. Menopause. 2014;21(8):823-833. doi: https://doi.org/10.1097/gme.0000000000000188.

24. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for Cancer Prevention: Global Perspective. Ann. Epidemiol. 2009;19(7):468-483. doi: https://doi.org/10.1016/j.annepidem.2009.03.021.


Review

For citations:


Rozhinskaya L.Y., Pigarova E.A., Bagretsova A.A., Verbovoy A.F., Kondratyeva N.G., Vasilevskaya O.A., Vasilyuk V.B., Manko M.V., Shunkov V.B., Grebennikova T.A. High-doses of cholecalciferol for vitamin D deficiency treatment: results of an open-label, multicenter, comparative, randomized trial. Osteoporosis and Bone Diseases. 2020;23(3):4-16. (In Russ.) https://doi.org/10.14341/osteo12697

Views: 3913


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)